Nurix Therapeutics NRIX
$ 24.04
-3.99%
Quarterly report 2024-Q3
added 10-11-2024
Country |
USA |
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
CEO |
Dr. Arthur T. Sands |
Employees in the company |
122 |
Shares |
54.3 M |
Market Cap[1] |
$ 1.31 B |
EBITDA (LTM) |
$ -174 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.